Latest Drug Delivery News

Page 1 of 6
Clinuvel has outlined a multi-year expansion from peptide therapeutics into polymers, long-acting injectables, devices and digital health, backed by A$220 million of planned FY2027-FY2030 spending. The strategy comes with a near-term setback: first patient treatment in the CUV107 vitiligo study has been delayed to February 2027.
Victor Sage
Victor Sage
6 Nov 2026
Argent BioPharma has granted Thai Phytomed International exclusive global commercialisation rights to four cannabis genotypes under a 10-year agreement. The deal preserves Argent’s ownership, but royalties depend on TPI generating profitable sales and securing approvals across multiple markets.
Victor Sage
Victor Sage
27 Oct 2026
Entropy Neurodynamics (ASX:ENP) reported a 30% rise in income and a narrower loss for FY26, driven by clinical progress in its IV-infused psilocin therapy TRP-8803, including promising Phase 2 results in Binge Eating Disorder and a new multi-indication basket study.
Ada Torres
Ada Torres
28 Aug 2026
LTR Pharma is shifting gears from clinical trials to commercial rollout, securing US partnerships for ROXUS and reporting encouraging SPONTAN Phase II data that supports FDA approval ambitions.
Ada Torres
Ada Torres
28 Aug 2026
Starpharma has successfully completed a $32 million entitlement offer, nearly fully subscribed, to fund its DEP® HER2-Lutetium Phase 1 trial and further develop its oncology pipeline.
Ada Torres
Ada Torres
11 Aug 2026
Argent BioPharma has eliminated US$5.5 million in secured debt through a global licensing agreement for its CannEpil® epilepsy therapy, while completing a key acquisition and advancing clinical trials in veterinary therapeutics.
Ada Torres
Ada Torres
28 July 2026
Adherium Limited has obtained a USD 1.65 million short-term unsecured loan from its major shareholder, Trudell Medical, to fund immediate working capital needs while pursuing capital structure adjustments.
Ada Torres
Ada Torres
29 June 2026
Invion Limited has partnered with South Korea's SANGMYUNG Innovation to explore its Photosoft™ photodynamic therapy for wet age-related macular degeneration, addressing a large unmet medical need in ophthalmology.
Ada Torres
Ada Torres
19 May 2026
Despite sweeping changes to Capital Gains Tax announced in the 2026/27 Federal Budget, Acrux Limited’s status as a Pooled Development Fund ensures its shareholders remain shielded from these new tax rules.
Ada Torres
Ada Torres
14 May 2026
Avecho Biotechnology has bolstered its cash reserves by $1.9 million through the exercise of listed options, positioning the company for a pivotal Phase III interim analysis readout for its insomnia treatment.
Ada Torres
Ada Torres
12 May 2026
Argent BioPharma secured a 48% stake in CannPal Animal Therapeutics, shipped its largest CannEpil® order to Ireland worth A$783,000, and filed a US provisional patent for its NanoBodies platform, underpinning its neuro-immune strategy and commercial growth.
Ada Torres
Ada Torres
29 Apr 2026
Acrux pivots from generics to developing a Female Testosterone therapy for HSDD, leveraging FDA feedback and a strong US market opportunity.
Ada Torres
Ada Torres
28 Apr 2026

Browse the archive

Full archive